CCS
MNTA

Crosspoint Capital Strategies’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Crosspoint Capital Strategies’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,365
Closed -$16K – 905
2015
Q4 		$16K Buy
+1,365
New +$22.8K ﹤0.01% 631

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Crosspoint Capital Strategies's MNTA Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2016, closing a stake of 1,365 shares — an estimated $16K sold.

Crosspoint Capital Strategies first reported a position in MNTA in Q4 2015 and held it in 1 quarter. The position peaked at $16K in Q4 2015. 148 funds tracked by Wall St. Rank hold MNTA as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,365 Momenta Pharmaceuticals, Inc. shares in Q1 2016, an estimated $16K.
  • Crosspoint Capital Strategies first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Momenta Pharmaceuticals, Inc. position peaked at $16K in Q4 2015.
  • 148 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.